| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 01/09/2013 | CN102861316A Stab wound and gunshot wound healing powder |
| 01/09/2013 | CN102861315A Preparation method of casein anticoagulant peptide oral liquid |
| 01/09/2013 | CN102860988A Chymotrypsin composition freeze-dried powder and preparation method thereof |
| 01/09/2013 | CN102166348B Application of inhibin recombinant fusion protein to preparing medicines for promoting oestrus and hybridization of sows |
| 01/09/2013 | CN102144980B LHRH (luteinizing hormone-releasing hormone antagonist) lyophilized powder injection with improved stability |
| 01/09/2013 | CN102107002B Compound trimebutine maleate composition and preparation method thereof |
| 01/09/2013 | CN102041263B Chicken alpha interferon/interleukin 2 chimeric gene |
| 01/09/2013 | CN101921319B Rubiaceae-type cyclopeptides, medicinal compositions using same as active ingredients, and preparation method and application thereof |
| 01/09/2013 | CN101822645B Controlled-release recombinant human bone morphogenic protein-2 poly-L-lactic acid microspheres and preparation method thereof |
| 01/09/2013 | CN101787078B Collagen polypeptide, preparation method and application thereof |
| 01/09/2013 | CN101765375B Iron fortification nutritional blend |
| 01/09/2013 | CN101636411B Interferon alpha 2a modified by polyethylene glycol, synthesis process and application thereof |
| 01/09/2013 | CN101596320B Medicament for treating tumor and application thereof |
| 01/09/2013 | CN101428009B Insulin intranasal inhalation powder spray |
| 01/09/2013 | CN101337988B New erythrocyte-stimulating factor analogues |
| 01/09/2013 | CN101160133B Preparation and composition of inter-alpha inhibitor proteins from human plasma for therapeutic use |
| 01/08/2013 | US8350021 Inhibiting expression of a polynucleotide sequence of hepatitis B virus and hepatitis C virus; mammalian cell comprising an expression construct; vectors |
| 01/08/2013 | US8350016 Oligonucleotide compositions and their use to induce apoptosis |
| 01/08/2013 | US8350008 WISP polypeptides and nucleic acids encoding same |
| 01/08/2013 | US8350003 Method of treatment of non-dermatophytic fungal infections |
| 01/08/2013 | US8349805 Use of Gonadorelin as a therapeutic agent |
| 01/08/2013 | US8349804 Bone graft and scaffolding materials immobilized with type I collagen binding peptides |
| 01/08/2013 | US8349803 Use of an active principle from flax for use in a composition for activating cytochrome c |
| 01/08/2013 | US8349802 Methods and compositions for contributing to the treatment of cancers |
| 01/08/2013 | US8349801 Peptide ligands for G-protein coupled receptors |
| 01/08/2013 | US8349799 Pharmaceutical composition of nanoparticles |
| 01/08/2013 | US8349798 Caveolin peptides and their use as therapeutics |
| 01/08/2013 | US8349797 Ligands of melanocortin receptors |
| 01/08/2013 | US8349796 Methods for treatment of distraction osteogenesis using PDGF |
| 01/08/2013 | US8349795 Resorbable thin membranes |
| 01/08/2013 | US8349794 Reconstitution medium for protein and peptide formulations |
| 01/08/2013 | US8349793 Method for treatment of inflammatory disease and disorder |
| 01/08/2013 | US8349792 Combination comprising CNDAC (2′-cyano-2′-deoxy-N4-palmitoyl-1-beta-D-arabinofuranosyl-cytosine) and a cytotoxic agent |
| 01/08/2013 | US8349791 Polypeptides that bind membrane proteins |
| 01/08/2013 | US8349349 Tissue adhesives and sealants and method for their use |
| 01/08/2013 | US8349334 Molecule |
| 01/08/2013 | US8349333 Allergy inhibitor compositions and kits and methods of using the same |
| 01/08/2013 | US8349323 Cytokine antagonists for neurological and neuropsychiatric disorders |
| 01/08/2013 | US8349319 Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency |
| 01/08/2013 | US8349318 Use of specifically engineered enzymes to enhance the efficacy of prodrugs |
| 01/08/2013 | US8349317 Use of L-carnitine or an alkanoyl L-carnitine, for the preparation of a dietary supplement or medicament for the treatment of corneal disease |
| 01/08/2013 | US8349312 Proline substituted cyclosporin analogues |
| 01/08/2013 | US8349311 Mutant interleukin-2 (IL-2) polypeptides |
| 01/08/2013 | US8349292 Treatment of allergic otitis media in mammals with Clostridia neurotoxins |
| 01/08/2013 | US8349012 Intervertebral disc treatment devices and methods |
| 01/08/2013 | CA2683610C Suspension formulations of insulinotropic peptides and uses thereof |
| 01/08/2013 | CA2677176C Inhibition of bcl-2 protein expression by liposomal antisense oligodeoxynucleotides |
| 01/08/2013 | CA2655644C Solution and method to reduce, treat and/or prevent oxidative stress and cell activation |
| 01/08/2013 | CA2642539C Agent for preventing arteriosclerosis, agent for suppressing vascular intimal thickening and agent for improving vascular endothelial function |
| 01/08/2013 | CA2637569C Pharmaceutical compositions with enhanced stability |
| 01/08/2013 | CA2605078C Plant-derived elastin binding protein ligands and methods of using the same |
| 01/08/2013 | CA2558771C Multiple promoter expression cassettes for simultaneous delivery of rnai agents |
| 01/08/2013 | CA2538342C Methods for treatment of insulin-like growth factor-1 (igf-1) deficiency |
| 01/08/2013 | CA2528591C Glp-1 analog fusion proteins |
| 01/08/2013 | CA2521987C Methods and compositions for increasing the anaerobic working capacity in tissues |
| 01/08/2013 | CA2500530C Therapeutic uses of .beta.-casein a2 and dietary supplement containing .beta.-casein a2 |
| 01/08/2013 | CA2495395C Method and device for multiplying and differentiating cells in the presence of growth factors and of a biological matrix or of a supporting structure |
| 01/08/2013 | CA2486245C Albumin having enhanced antimicrobial activity |
| 01/08/2013 | CA2485882C A therapeutic agent for mycobacterium tuberculosis comprising 15k granulysin as the active ingredient |
| 01/08/2013 | CA2449910C Use of glycoprotein for the treatment and re-epithelialisation of wounds |
| 01/08/2013 | CA2441577C Therapeutic agents for inflammatory bowel diseases |
| 01/08/2013 | CA2423595C Plasminogen activator to prevent corneal and subepithelial haze after laser vision correction surgery |
| 01/08/2013 | CA2388337C Method of inducing and/or enhancing an immune response to tumor antigens |
| 01/08/2013 | CA2385498C Method to enhance healing of sternum after sternotomy |
| 01/08/2013 | CA2341777C Neutral amino acid transporter and gene thereof |
| 01/08/2013 | CA2317727C Multipurpose antibody derivatives |
| 01/08/2013 | CA2305681C Apoptosis-related compounds and their use |
| 01/08/2013 | CA2285394C Antimicrobial prevention and treatment of human immunedeficiency virus and other infectious diseases |
| 01/08/2013 | CA2223608C Vaccine for porcine reproductive and respiratory syndrome virus |
| 01/04/2013 | CA2745987A1 Sorbent pellets including oxygen carriers |
| 01/03/2013 | WO2013003824A1 Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| 01/03/2013 | WO2013003808A1 Methods for modulating kallikrein (klkb1) expression |
| 01/03/2013 | WO2013003801A2 Inhibitor of neuronal connectivity linked to schizophrenia susceptibility and cognitive dysfunction |
| 01/03/2013 | WO2013003697A1 Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1) |
| 01/03/2013 | WO2013003689A2 Compositions containing nitro fatty acids |
| 01/03/2013 | WO2013003649A2 Wap domain fusion polypeptides and methods of use thereof |
| 01/03/2013 | WO2013003641A2 Serpin fusion polypeptides and methods of use thereof |
| 01/03/2013 | WO2013003606A1 Predictive biomarker of survival in the treatment of renal cell carcinoma |
| 01/03/2013 | WO2013003593A1 Methods of use of hsp70 for increased performance or hsp70 related disorders |
| 01/03/2013 | WO2013003579A1 Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of dengue virus infection |
| 01/03/2013 | WO2013003575A1 Method of administration and treatment |
| 01/03/2013 | WO2013003475A1 Inhibition of innate immune response |
| 01/03/2013 | WO2013003449A2 Methods of treatment with glp-1 receptor agonists |
| 01/03/2013 | WO2013003385A1 System and method for treatment of hemorrhagic stroke |
| 01/03/2013 | WO2013003356A1 Compositions, uses, and preparation of platelet lysates |
| 01/03/2013 | WO2013003346A2 Microrna-31 compositions and methods for use in autoimmune disease |
| 01/03/2013 | WO2013003045A2 Procoagulant peptides and their derivatives and uses therefor |
| 01/03/2013 | WO2013002819A1 Antibiotics and methods for manufacturing the same |
| 01/03/2013 | WO2013002733A1 Pharmaceutical compositions for treating cancer |
| 01/03/2013 | WO2013002485A2 Pharmaceutical composition for preventing and treating kidney disorders, containing inhibitor for phosphorylation of taz tyrosine as active ingredient for activation of nfat5/tonebp |
| 01/03/2013 | WO2013002331A1 Pharmaceutical preparation integrated with microneedles for skin treatment |
| 01/03/2013 | WO2013002317A1 Solid oxidized glutathione salt and method for producing same |
| 01/03/2013 | WO2013001830A1 Nucleoside antibiotic derivative |
| 01/03/2013 | WO2013001819A1 SOLUBLE INTEGRIN α4 MUTANT |
| 01/03/2013 | WO2013001517A1 Polypeptides and uses thereof for treatment of autoimmune disorders and infection |
| 01/03/2013 | WO2013000922A1 Ccr2 antagonist peptides |
| 01/03/2013 | WO2013000234A1 A novel recomnimant bifunctional fusion protein and its preparation and use |
| 01/03/2013 | WO2012149024A3 Dna aptamers for promoting remyelination |
| 01/03/2013 | WO2012148720A3 Anti-microbial peptides and methods of use thereof |
| 01/03/2013 | WO2012145680A3 Anti-microbial peptides and uses therefore |